Esmolol Hydrochloride

Atrial Fibrillation, Rapid Heartbeat, Sinus Tachycardia + 5 more

Treatment

20 Active Studies for Esmolol Hydrochloride

What is Esmolol Hydrochloride

Esmolol

The Generic name of this drug

Treatment Summary

Esmolol, also known by the brand name Brevibloc, is a medication that slows down the heart rate and reduces the force of heart contractions. It works by blocking the action of two chemicals, epinephrine and norepinephrine, and it has a fast onset but short duration of action. It is mostly used in medical settings to treat rapid heart rates and is generally safe and effective at recommended doses.

Esmolol Hydrochloride

is the brand name

Esmolol Hydrochloride Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Esmolol Hydrochloride

Esmolol

1986

49

Effectiveness

How Esmolol Hydrochloride works in the body

Esmolol is a type of drug called a beta-blocker. It works by blocking the effects of certain chemical messengers in the body. This decreases the activity of the heart, which can be useful in treating certain irregular heartbeats. Esmolol is more selective than some other beta-blockers, meaning that it mainly affects the heart and not other organs. At normal doses, it does not cause any additional stimulation of the heart. This makes it useful for treating arrhythmias, which are abnormal heart rates.

When to interrupt dosage

The recommended dosage of Esmolol Hydrochloride is contingent upon the determined condition, such as Supraventricular Tachycardia (SVT), heart rate irregularity and peri-operative period. The dosage depends upon the administration method (e.g. Liquid - Intravenous or Liquid) provided in the table underneath.

Condition

Dosage

Administration

Rapid Heartbeat

10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

Sinus Tachycardia

10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

Hypertensive disease

10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

Atrial Fibrillation

10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

Tachycardia, Supraventricular

10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

Tachycardia, Ventricular

10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

peri-operative period

10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

Arrhythmias, Cardiac

10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

Warnings

Esmolol Hydrochloride Contraindications

Condition

Risk Level

Notes

Shock, Cardiogenic

Do Not Combine

Sinus Bradycardia

Do Not Combine

Heart Block

Do Not Combine

Heart failure

Do Not Combine

There are 20 known major drug interactions with Esmolol Hydrochloride.

Common Esmolol Hydrochloride Drug Interactions

Drug Name

Risk Level

Description

4-Bromo-2,5-dimethoxyphenethylamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Esmolol.

4-Methoxyamphetamine

Major

The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Esmolol.

Abediterol

Major

The therapeutic efficacy of Abediterol can be decreased when used in combination with Esmolol.

Adrafinil

Major

The therapeutic efficacy of Adrafinil can be decreased when used in combination with Esmolol.

Agrostis gigantea pollen

Major

The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Esmolol.

Esmolol Hydrochloride Toxicity & Overdose Risk

Overdosing on Digoxin can lead to serious conditions such as cardiac arrest, slow heart rate, low blood pressure, and loss of consciousness.

image of a doctor in a lab doing drug, clinical research

Esmolol Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Esmolol Hydrochloride?

Currently, 243 active clinical trials are examining the potential of Esmolol Hydrochloride to regulate aberrant ventricular rate, Flutter, Atrial arrhythmia and peri-operative period.

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

103 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2, Early Phase 1

Sinus Tachycardia

0 Actively Recruiting

Tachycardia, Ventricular

0 Actively Recruiting

Arrhythmias, Cardiac

0 Actively Recruiting

peri-operative period

0 Actively Recruiting

Tachycardia, Supraventricular

0 Actively Recruiting

Rapid Heartbeat

3 Actively Recruiting

Phase 1, Phase 2, Not Applicable

Hypertensive disease

41 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2

Esmolol Hydrochloride Reviews: What are patients saying about Esmolol Hydrochloride?

4.3

Patient Review

6/4/2009

Esmolol Hydrochloride for Having a Rapid Heart Action - Supraventricular Tachycardia

This drug, in combination with atrial lead wire placement, saved my father's life. He had a massive AMI on 5-10-09 and was experiencing recurrent VT and VFib afterwards. The medication has been working great so far; as of 06-03-09, he is doing much better.

Patient Q&A Section about esmolol hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is esmolol used for?

"Esmolol is used to control rapid heartbeats or abnormal heart rhythms. This medicine is also used to treat fast heartbeat and high blood pressure during surgery, after surgery, or during other medical procedures."

Answered by AI

What does esmolol do to the heart?

"This medicine is a beta-blocker. It affects the response to nerve impulses in certain parts of the body, such as the heart. As a result, the heart beats slower and decreases the blood pressure."

Answered by AI

What drug class is esmolol?

"Esmolol is a short-acting, cardio-selective beta-blocker that works by antagonizing the beta-1-adrenergic receptors primarily in the myocytes."

Answered by AI

How long does it take esmolol to work?

"If no loading doses are given, it will take about 30 minutes for the effects of esmolol to reach a steady state."

Answered by AI

Clinical Trials for Esmolol Hydrochloride

Image of Allegheny General Hospital in Pittsburgh, United States.

Bachmann's Bundle vs Right Atrial Appendage Pacing for Atrial Fibrillation

18+
All Sexes
Pittsburgh, PA

Participants will be randomly assigned to one of two clinical treatment Arms, both of which are standard care procedures performed in the right atrium (RA): Arm A: Pacing from the Bachmann's Bundle (BB) in the right atrium (upper right chamber of the heart) Arm B: Pacing from the right atrial appendage (RAA - a sac attached to the right atrium) Neither of these treatments are experimental; both are routinely performed by Electrophysiologists in the clinical setting. The purpose of this study is to compare side by side these two treatments and evaluate if one is better than the other. After the procedure, participants will be followed for one year. Medical record data will be collected, and a blood sample will be collected upon enrollment and at one year after implantation. Research-related surveys will be completed at the standard-care 3-, 6-, and 12-month visits.

Recruiting
Has No Placebo

Allegheny General Hospital

Joshua Silverstein, MD

Medtronic

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Barber and Pharmacist Coordination for High Blood Pressure

35 - 79
Male
Los Angeles, CA

The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged. The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men." It will build upon the foundational work of the original study and telemedicine pilot by evaluating the efficacy of a fully remote hypertension management program.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Christine Albert, MD, MPH

Image of Foothills Medical Center in Calgary, Canada.

Spinal Cord Stimulation for High Blood Pressure

18+
All Sexes
Calgary, Canada

High blood pressure, also called hypertension, raises the risk of heart disease, stroke, and kidney disease. Medications work well for many people, but some people still have blood pressure that stays too high, or they have side effects from their medications. Researchers are looking for treatments that do not involve taking more medication. Nerves help control blood pressure by changing how blood vessels tighten and how hard the heart pumps. Because of this, treatments that act on nerves may be able to lower blood pressure. Spinal cord stimulation is a treatment already used to manage long-term pain. It uses a small device, placed under the skin during a standard operation, that sends mild electrical signals to the spine. Laboratory studies suggest that stimulating the lower part of the mid-back may also lower blood pressure, but this has not been carefully studied in people who already use these devices. This study will look at whether changing the settings on a spinal cord stimulator affects blood pressure. About 11 adults who have high blood pressure and who already have a spinal cord stimulator for long-term pain. No new device will be placed, and no surgery or other invasive procedure will be done for this study. Participants attend a series of study visits. At each visit, trained staff record blood pressure and heart rate while the stimulator is turned on, turned off, and set to other settings that the person's care team has approved and that the person finds comfortable. There are rest breaks between each setting. Over successive visits, the study team works to identify the settings that best lower blood pressure. Participants can stop at any time, and their usual settings are restored at the end of each visit. The study will also look at whether this kind of testing is practical and comfortable for participants. The results will help researchers decide whether larger studies of spinal cord stimulation for blood pressure control are worth doing.

Waitlist Available
Has No Placebo

Foothills Medical Center

Aaron Phillips, PhD

Have you considered Esmolol Hydrochloride clinical trials?

We made a collection of clinical trials featuring Esmolol Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington in Arlington, United States.

Alcohol Abstinence for High Blood Pressure

26 - 49
All Sexes
Arlington, TX

The purpose of this study is to learn whether avoiding alcohol can improve heart and blood vessel health in adults who regularly drink alcohol and have high blood pressure. High blood pressure is a major risk factor for cardiovascular disease (CVD), including heart attack and stroke. In this randomized, controlled trial, men and women aged 26 to 49 years who regularly consume alcohol and have high blood pressure will be assigned by chance to either stop drinking alcohol or continue their usual drinking habits for 8 weeks. Researchers will compare changes in blood pressure and other cardiovascular disease risk factors between the two groups. The information gained from this study may help researchers and health care providers better understand the effects of alcohol consumption on cardiovascular health and whether alcohol abstinence can reduce heart disease risk, especially in adults with high blood pressure.

Recruiting
Has No Placebo

Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington

Image of Department of Family & Community Medicine; University of Alabama at Birmingham in Birmingham, United States.

Treatment for High Blood Pressure

18+
All Sexes
Birmingham, AL

The researchers will invite 30 patients in primary care who have high blood pressure to participate in this health program with a supportive partner of their choosing (these will be the "participant pairs"). Participant pairs will be invited to complete the Heart Care Pairs health program that will include up to six sessions each including 1) some education on a health habit like physical activity and heart healthy foods, 2) goal setting together, and 3) talk about healthy communication to support one another with heart healthy habits. The researchers will work with participants to address things that get in the way of coming for visits like offering transportation and offering telehealth visits. The researchers are seeing how this program works in real life so participants will be asked to complete as many sessions as they want to and can attend. The researchers will be interested in what participants think about the sessions, if they were satisfied with the visits, and if they would recommend the program to others in their community. The researchers will ask these questions in interviews with participants. The researchers will also ask up to 25 primary care workers about how they view the program as helpful to their work with patients with high blood pressure and whether they would refer more patients to the program in the future.

Waitlist Available
Has No Placebo

Department of Family & Community Medicine; University of Alabama at Birmingham

Image of London Health Sciences Centre (LHSC) in London, Canada.

BASIC-S Intervention for Cardiovascular Risk

18+
All Sexes
London, Canada

Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging. To address this, we developed BASIC-S (Blood Pressure, Activity, Sleep, Interaction, Consumption, and Support), a framework targeting Blood pressure, Activity, Sleep, Interaction (socially), Consumption (nutrition), and Support using partner support and motivational interviewing. This individual-focused approach bypasses the logistical and financial barriers of complex clinical interventions by using sustained behavioral science to support gradual lifestyle changes. This study is a single-center, mixed-methods, cluster-randomized pilot trial evaluating the feasibility of the BASIC-S protocol in an occupational setting. A maximum of 60 households (120 participants) will be randomized 1:1 to either the BASIC-S intervention (motivational coaching, secure video check-ins, automated text messages, and a digital workbook) or standard care. Outcomes will assess feasibility, acceptability, and the validity of new tracking metrics to inform a future full-scale trial.

Waitlist Available
Has No Placebo

London Health Sciences Centre (LHSC)

Have you considered Esmolol Hydrochloride clinical trials?

We made a collection of clinical trials featuring Esmolol Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of NeuroFit Lab, Ivor Wynne Centre, McMaster University in Hamilton, Canada.

Isometric Handgrip Exercise for High Blood Pressure

65+
All Sexes
Hamilton, Canada

The goal of this clinical trial is to evaluate whether a short, supervised isometric handgrip exercise program is feasible and acceptable for older adults with elevated blood pressure or hypertension. It will also explore whether this type of exercise may improve blood pressure and cognitive function. The main questions it aims to answer are: * Is this handgrip exercise program practical and acceptable for older adults to participate in within a community exercise setting? * Does participation in the program lead to changes in blood pressure and cognitive function? Researchers will compare two handgrip devices to determine whether the method of delivering the exercise influences feasibility and outcomes. Participants will: * Be randomly assigned to use one of two handgrip devices. * Complete supervised exercise sessions twice per week for 4 weeks. * Perform brief handgrip contractions at a set intensity during each session. * Complete blood pressure and cognitive assessments before and after the program.

Recruiting
Has No Placebo

NeuroFit Lab, Ivor Wynne Centre, McMaster University (+1 Sites)

Jennifer Heisz, PhD

Image of North Shore University Hospital in Manhasset, United States.

CT Scan for Atrial Fibrillation

18+
All Sexes
Manhasset, NY

This study aims to investigate whether a quick, additional CT scan of the heart, performed immediately after a standard CT scan for pulmonary embolism, can effectively detect blood clots in the left atrial appendage (LAA) in patients with atrial fibrillation. Detecting these clots is crucial before certain heart procedures to prevent stroke. Currently, a different, more involved procedure (Transesophageal Echocardiography - TEE) is often used. This study will assess if this additional CT scan is feasible, meaning if it can provide clear enough images to identify LAA clots without needing more contrast dye. The study will involve 60 patients, half receiving an "ungated" CT scan and the other half a "gated" CT scan (timed with their heart rhythm). The results of these scans will not be used for immediate patient care during the study, but rather to evaluate the CT scan technique itself. There is no direct benefit to participants, but the information gained could lead to faster diagnosis and reduced unnecessary testing for future patients.

Waitlist Available
Has No Placebo

North Shore University Hospital

Canon Medical Systems, USA

Image of SEC Clinical Research in Dothan, United States.

REGN7508 + Apixaban for Atrial Fibrillation

18+
All Sexes
Dothan, AL

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Phase 3
Recruiting

SEC Clinical Research (+43 Sites)

Clinical Trial Management

Regeneron Pharmaceuticals

Image of UCHealth University of Colorado Hospital - Cardiology in Aurora, United States.

BAY 3670549 for Atrial Fibrillation

18 - 85
All Sexes
Aurora, CO

The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called electrical cardioversion. Electrical cardioversion is a procedure that helps the heart return to a normal rhythm. In this study, each participant will get a single intravenous (IV) infusion of either BAY 3670549 or a placebo. Participants will then be observed to see whether the heart rhythm returns to a normal rhythm. If it does not, electrical cardioversion can still be performed as planned. The study will look at how many participants return from AF to a normal rhythm, without needing electrical cardioversion and how long it takes. It will also show how many participants experience medical problems after treatment and how BAY 3670549 move into, through and out of the participants' body. The total duration of the study for an individual participant may be up two months. The findings from this study may contribute to the development of a new treatment option for people with AF.

Phase 2
Recruiting

UCHealth University of Colorado Hospital - Cardiology (+5 Sites)

Bayer

Have you considered Esmolol Hydrochloride clinical trials?

We made a collection of clinical trials featuring Esmolol Hydrochloride, we think they might fit your search criteria.
Go to Trials